- Report
- June 2023
- 364 Pages
Global
From €4771EUR$5,164USD£3,950GBP
- Report
- February 2024
- 175 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- February 2024
- 175 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- February 2024
- 175 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- February 2024
- 175 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- January 2024
- 200 Pages
Global
From €4781EUR$5,000USD£4,097GBP
- Report
- February 2024
- 187 Pages
Global
From €3442EUR$3,600USD£2,950GBP
- Report
- February 2024
- 196 Pages
Global
From €3442EUR$3,600USD£2,950GBP
- Report
- January 2024
- 200 Pages
Global
From €3968EUR$4,150USD£3,401GBP
- Report
- November 2023
- 30 Pages
Global
From €2630EUR$2,750USD£2,253GBP
- Report
- November 2023
- 30 Pages
Global
From €3108EUR$3,250USD£2,663GBP
- Report
- November 2023
- 181 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- November 2023
- 190 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- November 2023
- 185 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- October 2023
- 180 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- October 2023
- 181 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- October 2023
- 178 Pages
Global
From €4686EUR$4,900USD£4,015GBP
- Report
- March 2024
- 163 Pages
Global
From €2391EUR$2,500USD£2,049GBP
- Report
- July 2023
- 160 Pages
Global
From €2391EUR$2,500USD£2,049GBP
- Report
- May 2022
- 231 Pages
Global
From €4589EUR$4,799USD£3,932GBP
The Vaccine Adjuvant market is a subset of the Vaccines market, which is composed of products that are used to enhance the effectiveness of vaccines. Vaccine adjuvants are substances that are added to vaccines to increase the body's immune response to the vaccine. Adjuvants can be either natural or synthetic, and can be used to increase the potency of a vaccine, reduce the amount of antigen needed, or to extend the duration of the vaccine's effectiveness. Vaccine adjuvants are used in a variety of vaccines, including those for influenza, hepatitis, and human papillomavirus.
Some companies in the Vaccine Adjuvant market include GlaxoSmithKline, Merck, Sanofi, and Novartis. Show Less Read more